Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset ANCA-Associated Vasculitis: An ARChiVe registry-cohort study.
Gagne SJ, Sivaraman V, Bosman ES, Klamer B, Morishita KA, Huber A, Orjuela A, Eberhard B, Myrup C, Gerstbacher D, Foell D, Al-Abadi E, McErlane F, Cook K, Wagner-Weiner L, Elder M, Moorthy LN, Dancey P, Yeung R, Khubchandani R, Deepak S, Charuvanij S, Tarvin S, Shenoi S, Tanner T, Brown K, Cabral DA; ARChiVe Investigators Network within the PedVas Initiative. Gagne SJ, et al. Arthritis Care Res (Hoboken). 2024 Oct 28. doi: 10.1002/acr.25455. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39467015
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
Mannion ML, Amin S, Balevic S, Chang ML, Correll CK, Kearsley-Fleet L, Hyrich KL, Beukelman T; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators. Mannion ML, et al. Arthritis Care Res (Hoboken). 2024 Aug;76(8):1090-1098. doi: 10.1002/acr.25339. Epub 2024 May 7. Arthritis Care Res (Hoboken). 2024. PMID: 38556945
Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.
Saper VE, Tian L, Verstegen RHJ, Conrad CK, Cidon M, Hopper RK, Kuo CS, Osoegawa K, Baszis K, Bingham CA, Ferguson I, Hahn T, Horne A, Isupova EA, Jones JT, Kasapcopur Ö, Klein-Gitelman MS, Kostik MM, Ozen S, Phadke O, Prahalad S, Randell RL, Sener S, Stingl C, Abdul-Aziz R, Akoghlanian S, Al Julandani D, Alvarez MB, Bader-Meunier B, Balay-Dustrude EE, Balboni I, Baxter SK, Berard RA, Bhattad S, Bolaria R, Boneparth A, Cassidy EA, Co DO, Collins KP, Dancey P, Dickinson AM, Edelheit BS, Espada G, Flanagan ER, Imundo LF, Jindal AK, Kim HA, Klaus G, Lake C, Lapin WB, Lawson EF, Marmor I, Mombourquette J, Ogunjimi B, Olveda R, Ombrello MJ, Onel K, Poholek C, Ramanan AV, Ravelli A, Reinhardt A, Robinson AD, Rouster-Stevens K, Saad N, Schneider R, Selmanovic V, Sefic Pasic I, Shenoi S, Shilo NR, Soep JB, Sura A, Taber SF, Tesher M, Tibaldi J, Torok KS, Tsin CM, Vasquez-Canizares N, Villacis Nunez DS, Way EE, Whitehead B, Zemel LS, Sharma S, Fernández-Viña MA, Mellins ED; CARRA Registry Investigators. Saper VE, et al. J Allergy Clin Immunol Pract. 2024 Nov;12(11):2996-3013.e7. doi: 10.1016/j.jaip.2024.07.002. Epub 2024 Aug 15. J Allergy Clin Immunol Pract. 2024. PMID: 39002722
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research.
Chang MH, Barbar-Smiley F, Akoghlanian S, Drew J, Angeles-Han ST, Quinlan-Waters M, Bohnsack JF, Cooper AM, Edelheit B, Twachtman-Bassett J, Lerman MA, Nanda K, Rabinovich CE, Lo MS; CARRA Uveitis Workgroup and the CARRA Registry Investigators. Chang MH, et al. Pediatr Rheumatol Online J. 2024 Oct 7;22(1):88. doi: 10.1186/s12969-024-01022-x. Pediatr Rheumatol Online J. 2024. PMID: 39375683 Free PMC article.
18 results